brea lipe

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Robert Graham G Russell

University of Oxford

UNITED KINGDOM

View details

Kearin Reid

Independent Information Professional

UNITED STATES

View details

Mohammad Ansari

Chief

UNITED STATES

View details

Muhamed Baljevic

Associate Professor of Medicine, Director, Plasma Cell Disorders Research and Vanderbilt Amyloidosis (VAMP) Programs

UNITED STATES

View details

Shakira J. Grant

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

brea lipe

Research Interests

Explore related searches

Contact this professor

Articles (10)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies.

Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.

Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.

SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma.

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.

Bisphosphonates for delivering drugs to bone.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

Collaborators (5)

Robert Graham G Russell

Kearin Reid

Mohammad Ansari

Muhamed Baljevic

Shakira J. Grant

Make your next move.